Home  >  Products  >  HCAR2 (hydroxycarboxylic acid receptor 2 ) Blocking Peptide (the C terminal of HCAR2)(100ug)
HCAR2 (hydroxycarboxylic acid receptor 2 ) Blocking Peptide (the C terminal of HCAR2)(100ug)

HCAR2 (hydroxycarboxylic acid receptor 2 ) Blocking Peptide (the C terminal of HCAR2)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-HCAR2 Antibody (ARP63888_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP63888
Size: 100ug
Weight: 42kDa
Gene: 338442
Format: Lyophilized powder
Target: HCAR2 acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.
Alternative names: HM74a; HM74b; NIACR1; PUMAG; Puma-g
See Full Product Listings >